A Phase II Study of M2951 in SLE

Inclusion Criteria:

• Eligible male and female participants, aged 18 to 75 years
• Must have diagnosis of SLE with either the Systemic Lupus International CollaboratingClinics (SLICC) criteria for SLE, or at least four of the 11 American College ofRheumatology (ACR) classification criteria for SLE, of at least six months durationprior to Screening
• SLEDAI-2K total score greater than or equal to (>=) 6 (including clinical SLEDAIgreater than or equal to (>=) 4) at Screening Visit
• And be positive for anti-double-stranded Deoxyribonucleic Acid (DNA) and/oranti-nuclear antibody (ANA greater than or equal to (>=) 1:80) and/or anti-Smith (anti-Sm) antibody at the time of Screening
• Other protocol defined inclusion criteria could apply

Exclusion Criteria:

• Participants are not eligible for this study if they have active, clinicallysignificant interstitial lung disease or pulmonary arterial hypertension
• Proteinuria (urine protein to creatinine ratio [UPCR] > 4 mg/mg)
• Acutely worsened renal function
• Central nervous system SLE
• Or within two weeks prior to Screening or during Screening: use of oralcorticosteroids greater than (>) 30 mg daily prednisone equivalent
• Use of injectable corticosteroids, or change in dose of corticosteroids.
• Other protocol defined exclusion criteria could apply